MA31845B1 - Pipéridino-dihydrothiénopyrimidines substituées - Google Patents
Pipéridino-dihydrothiénopyrimidines substituéesInfo
- Publication number
- MA31845B1 MA31845B1 MA32832A MA32832A MA31845B1 MA 31845 B1 MA31845 B1 MA 31845B1 MA 32832 A MA32832 A MA 32832A MA 32832 A MA32832 A MA 32832A MA 31845 B1 MA31845 B1 MA 31845B1
- Authority
- MA
- Morocco
- Prior art keywords
- dihydrothienopyrimidines
- diseases
- formula
- relates
- piperidino
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- JMUGMZBGUVOSPU-UHFFFAOYSA-N 1-piperidin-1-yl-2h-thieno[3,2-d]pyrimidine Chemical class C1CCCCN1N1C(C=CS2)=C2C=NC1 JMUGMZBGUVOSPU-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne de nouvelles pipéridino- dihydrothiénopyrimidines de formule (1), ainsi que leurs sels pharmacologiquement compatibles. Dans la formule, x représente so ou so2, de préférence so, et r1, r2, r3 et r4 ont la signification indiquée dans la revendication 1. L'invention concerne également des compositions pharmaceutiques contenant ces composés. Ces nouvelles pipéridino- dihydrothiénopyrimidines sont appropriées pour le traitement des troubles ou des affections des voies respiratoires ou gastro-intestinales, des maladies inflammatoires des articulations, de la peau ou des yeux, des maladies du système nerveux périphérique ou central ou des maladies cancéreuses.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118901 | 2007-10-19 | ||
| PCT/EP2008/063999 WO2009050248A1 (fr) | 2007-10-19 | 2008-10-16 | Pipéridino-dihydrothiénopyrimidines substituées |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31845B1 true MA31845B1 (fr) | 2010-11-01 |
Family
ID=39154006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32832A MA31845B1 (fr) | 2007-10-19 | 2010-05-12 | Pipéridino-dihydrothiénopyrimidines substituées |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8754073B2 (fr) |
| EP (3) | EP2380891B1 (fr) |
| JP (2) | JP5150728B2 (fr) |
| KR (1) | KR101548975B1 (fr) |
| CN (2) | CN104069112A (fr) |
| AR (1) | AR069075A1 (fr) |
| AT (1) | ATE542825T1 (fr) |
| AU (1) | AU2008313660B2 (fr) |
| BR (1) | BRPI0818006B8 (fr) |
| CA (1) | CA2705414C (fr) |
| CL (1) | CL2008003096A1 (fr) |
| CY (2) | CY1112703T1 (fr) |
| DK (2) | DK2215092T3 (fr) |
| EA (1) | EA019480B1 (fr) |
| EC (1) | ECSP10010156A (fr) |
| ES (2) | ES2381452T3 (fr) |
| HR (2) | HRP20120334T1 (fr) |
| MA (1) | MA31845B1 (fr) |
| ME (1) | ME01330B (fr) |
| MX (1) | MX2010004026A (fr) |
| MY (1) | MY153979A (fr) |
| NZ (1) | NZ585346A (fr) |
| PE (2) | PE20091386A1 (fr) |
| PL (2) | PL2215092T3 (fr) |
| PT (2) | PT2610258E (fr) |
| RS (1) | RS52271B (fr) |
| SI (2) | SI2610258T1 (fr) |
| TN (1) | TN2010000175A1 (fr) |
| TW (1) | TWI421077B (fr) |
| UA (1) | UA99309C2 (fr) |
| UY (1) | UY31405A1 (fr) |
| WO (1) | WO2009050248A1 (fr) |
| ZA (1) | ZA201001683B (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1847543A1 (fr) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidines pour le traitement de maladies inflammatoires |
| CA2702500A1 (fr) * | 2007-10-18 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Preparation de dihydrothienopyrimidines et d'intermediaires utilises lors de celle-ci |
| EP2205609B1 (fr) | 2007-10-19 | 2017-03-29 | Boehringer Ingelheim International GmbH | Composés pipérazino-dihydro-thiénopyrimidine substituées par un hétérocycle |
| JP5563466B2 (ja) | 2007-10-19 | 2014-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピペラジノ−ジヒドロチエノピリミジン誘導体 |
| BRPI0818006B8 (pt) * | 2007-10-19 | 2021-05-25 | Boehringer Ingelheim Int | compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas |
| WO2010097334A1 (fr) * | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Associations de médicaments contenant des inhibiteurs de pde4 et des ains |
| US20130225609A1 (en) | 2010-04-08 | 2013-08-29 | Boehringer Ingelheim International Gmbh | Combinations of medicaments, containing pde4-inhibitors and ep4-receptor-antagonists |
| US8877758B2 (en) | 2010-04-08 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US20130059866A1 (en) * | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| US9013997B2 (en) * | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US9499519B2 (en) | 2012-12-26 | 2016-11-22 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| JP6307525B2 (ja) | 2013-02-04 | 2018-04-04 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 新規の置換縮合ピリミジン化合物 |
| WO2014124860A1 (fr) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Inhibiteurs spécifiques de pde4b pour le traitement du diabète sucré |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| CN104892720B (zh) * | 2014-03-07 | 2016-10-26 | 华东师范大学 | 4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用 |
| EP3480198B1 (fr) * | 2016-06-30 | 2021-05-05 | Riken | Nouveau composé ou son sel pharmaceutiquement acceptable |
| EP3684775B1 (fr) * | 2017-09-20 | 2024-11-20 | UNION therapeutics A/S | Dihydrothiénopyrimidines substituées, et leur utilisation en tant qu'inhibiteurs de la phosphodiestérase |
| DK3700529T3 (da) | 2017-10-23 | 2025-09-22 | Boehringer Ingelheim Int | Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild) |
| US11299497B2 (en) | 2017-12-15 | 2022-04-12 | UNION therapeutics A/S | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
| ES2968822T3 (es) | 2017-12-15 | 2024-05-14 | Union Therapeutics As | Azetidina dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa |
| ES2935615T3 (es) * | 2017-12-15 | 2023-03-08 | Union Therapeutics As | Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa |
| WO2020048827A1 (fr) * | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de la 1,3,9-triazaspiro[5.5]undécan-2-one |
| US20230181590A1 (en) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases |
| IL312742A (en) | 2021-12-09 | 2024-07-01 | Boehringer Ingelheim Int | New therapeutic combinations for the treatment of advanced lymphoid interstitial lung diseases |
| EP4534540A1 (fr) * | 2022-06-02 | 2025-04-09 | Xizang Haisco Pharmaceutical Co., Ltd. | Inhibiteur de pde4b et son utilisation |
| WO2023241684A1 (fr) * | 2022-06-16 | 2023-12-21 | 武汉人福创新药物研发中心有限公司 | Inhibiteur de pde4b |
| CN115040503B (zh) * | 2022-07-26 | 2023-10-10 | 云南民族大学 | 螺环二烯酮型木脂素类化合物在制药中的应用 |
| CN119630673A (zh) * | 2022-08-09 | 2025-03-14 | 西藏海思科制药有限公司 | Pde4b抑制剂及其用途 |
| EP4593838A1 (fr) | 2022-09-28 | 2025-08-06 | Boehringer Ingelheim International GmbH | Utilisation de biomarqueurs dans le traitement d'états fibrotiques avec inhibiteur de la pde4b |
| JP2025534418A (ja) * | 2022-09-29 | 2025-10-15 | 蘇州愛科百発生物医薬技術有限公司 | 含窒素縮合複素環化合物、その調製方法、および医薬におけるその使用 |
| IL322980A (en) * | 2023-02-28 | 2025-10-01 | Innovstone Therapeutics Ltd | Dihydrothionopyrimidine derivatives and their uses |
| WO2024208225A1 (fr) * | 2023-04-03 | 2024-10-10 | 上海壹迪生物技术有限公司 | Composé dihydrothiénopyrimidine, son procédé de préparation et son utilisation |
| WO2024213089A1 (fr) | 2023-04-13 | 2024-10-17 | 上海壹迪生物技术有限公司 | Composé dihydrothiénopyrimidine substitué, son procédé de préparation et son utilisation |
| CN116925099B (zh) * | 2023-07-21 | 2025-06-03 | 厦门大学 | 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物 |
| WO2025038987A2 (fr) * | 2023-08-17 | 2025-02-20 | Katalytic Therapeutics, Inc. | Agents de dégradation de protéine pde4, compositions pharmaceutiques et applications thérapeutiques |
| WO2025067168A1 (fr) * | 2023-09-25 | 2025-04-03 | 苏州爱科百发生物医药技术有限公司 | Composé cyclique fusionné d'aza, son procédé de préparation et son utilisation |
| CN120398908A (zh) * | 2024-02-01 | 2025-08-01 | 艾派克斯生物科技有限公司 | Pde4b抑制剂及其药物组合物和用途 |
| WO2025162431A1 (fr) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | Composition pharmaceutique orale de composé inhibiteur de pde4b et son procédé de préparation |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470336A1 (de) * | 1962-07-04 | 1969-03-20 | Thomae Gmbh Dr K | Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung |
| NL124131C (fr) | 1963-06-17 | |||
| DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| NL123139C (fr) | 1965-03-31 | |||
| BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
| DE2032687A1 (en) | 1970-07-02 | 1972-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa |
| DE1940572A1 (de) | 1969-08-08 | 1971-02-11 | Thomae Gmbh Dr K | Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| FR2082496A5 (fr) | 1970-03-18 | 1971-12-10 | Westinghouse Freins & Signaux | |
| DE2121950A1 (en) | 1971-05-04 | 1972-11-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity |
| DE2750288A1 (de) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US4256737A (en) * | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| US5187168A (en) * | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
| US5491201A (en) | 1992-02-06 | 1996-02-13 | The Dow Chemical Company | Mesogenic cyclic imino ether-containing compositions and polymerization products thereof |
| JPH07330777A (ja) | 1994-06-08 | 1995-12-19 | Taisho Pharmaceut Co Ltd | チエノ［３，２−ｄ］ピリミジン−４−オン誘導体 |
| JPH09301958A (ja) | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
| US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| AU2001229501A1 (en) | 2000-01-24 | 2001-07-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of inducible nitric oxide synthase expression |
| GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| AP1572A (en) | 2000-10-12 | 2006-02-13 | Boehringer Ingelheim Pharma | Crystalline monohydrate, method for producing the same and use thereof in the production of a medicament. |
| DE10064994A1 (de) * | 2000-12-23 | 2002-07-04 | Merck Patent Gmbh | Sulfamidothienopyrimidine |
| WO2002088138A1 (fr) | 2001-04-30 | 2002-11-07 | Bayer Corporation | Nouveaux thiopheno[2,3-d]pyrimidines 4-amino-5,6-substitutes |
| AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| PL208137B1 (pl) | 2001-06-22 | 2011-03-31 | Boehringer Ingelheim Pharma | Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium |
| US6587548B2 (en) * | 2001-07-17 | 2003-07-01 | Hewlett-Packard Development Co., L.P. | Method and system of using a single telephone number for multiple services |
| AU2002364211A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| WO2003059913A1 (fr) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Inhibiteurs de la rho-kinase |
| SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| CA2523831C (fr) | 2003-04-29 | 2008-11-18 | Pfizer Inc. | 5,7-diaminopyrazolo[4,3]d!pyrimidines utiles pour le traitement de l'hypertension |
| US20050084878A1 (en) | 2003-05-16 | 2005-04-21 | Wisconsin Alumni Research Foundation | Method for isolating and cloning high molecular weight polynucleotide molecules from the environment |
| JP2005003345A (ja) | 2003-05-21 | 2005-01-06 | Showa Denko Kk | 換気兼熱交換装置および空調システム |
| CA2540617A1 (fr) * | 2003-10-02 | 2005-04-21 | Martek Biosciences Corporation | Production de niveaux eleves de dha dans des micro-algues au moyen de quantites modifiees de chlorure et de potassium |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
| ES2340855T3 (es) | 2003-12-23 | 2010-06-10 | Serodus As | Modulares de receptores 5-ht perifericos. |
| WO2005082865A1 (fr) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | Dérivé de pyrimidine bicyclique fondu |
| GB0427403D0 (en) | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
| CN101163706A (zh) | 2005-04-21 | 2008-04-16 | 贝林格尔·英格海姆国际有限公司 | 用于治疗炎性疾病的二氢噻吩并嘧啶 |
| CN101171005A (zh) | 2005-05-11 | 2008-04-30 | 尼科梅德有限责任公司 | Pde4抑制剂罗氟司特与四氢生物蝶呤衍生物的组合 |
| EP1847543A1 (fr) * | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidines pour le traitement de maladies inflammatoires |
| WO2008128942A1 (fr) | 2007-04-20 | 2008-10-30 | Glaxo Group Limited | Composés contenant de l'azote tricyclique utilisés en tant qu'agents antibactériens |
| CA2702500A1 (fr) | 2007-10-18 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Preparation de dihydrothienopyrimidines et d'intermediaires utilises lors de celle-ci |
| CA2702922C (fr) | 2007-10-19 | 2018-01-16 | Schering Corporation | Derives de 1,3,4-thiadiazole spiro-condenses pour inhiber l'activite de la kinesine ksp |
| BRPI0818006B8 (pt) * | 2007-10-19 | 2021-05-25 | Boehringer Ingelheim Int | compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas |
| JP5563466B2 (ja) * | 2007-10-19 | 2014-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピペラジノ−ジヒドロチエノピリミジン誘導体 |
| TW200934771A (en) * | 2007-10-19 | 2009-08-16 | Astrazeneca Ab | New compounds |
| WO2009053268A1 (fr) | 2007-10-19 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Nouvelles pipérazino-dihydrothiénopyrimidines phényl-substituées |
| EP2205609B1 (fr) * | 2007-10-19 | 2017-03-29 | Boehringer Ingelheim International GmbH | Composés pipérazino-dihydro-thiénopyrimidine substituées par un hétérocycle |
| FR2922550B1 (fr) * | 2007-10-19 | 2009-11-27 | Sanofi Aventis | Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet |
| CA2753597A1 (fr) * | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Combinaisons de medicaments contenant des inhibiteurs de pde4 et des ains |
| WO2010097334A1 (fr) | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Associations de médicaments contenant des inhibiteurs de pde4 et des ains |
| US20130059866A1 (en) * | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
-
2008
- 2008-10-16 BR BRPI0818006A patent/BRPI0818006B8/pt active IP Right Grant
- 2008-10-16 EP EP11174754.9A patent/EP2380891B1/fr active Active
- 2008-10-16 MX MX2010004026A patent/MX2010004026A/es active IP Right Grant
- 2008-10-16 ES ES08839793T patent/ES2381452T3/es active Active
- 2008-10-16 US US12/738,344 patent/US8754073B2/en active Active
- 2008-10-16 AT AT08839793T patent/ATE542825T1/de active
- 2008-10-16 EP EP13154790.3A patent/EP2610258B1/fr active Active
- 2008-10-16 ME MEP-2012-26A patent/ME01330B/fr unknown
- 2008-10-16 RS RS20120144A patent/RS52271B/sr unknown
- 2008-10-16 DK DK08839793.0T patent/DK2215092T3/da active
- 2008-10-16 KR KR1020107010905A patent/KR101548975B1/ko active Active
- 2008-10-16 UA UAA201005780A patent/UA99309C2/ru unknown
- 2008-10-16 JP JP2010529389A patent/JP5150728B2/ja active Active
- 2008-10-16 DK DK13154790.3T patent/DK2610258T3/da active
- 2008-10-16 WO PCT/EP2008/063999 patent/WO2009050248A1/fr not_active Ceased
- 2008-10-16 SI SI200831314T patent/SI2610258T1/sl unknown
- 2008-10-16 AU AU2008313660A patent/AU2008313660B2/en active Active
- 2008-10-16 HR HRP20120334AT patent/HRP20120334T1/hr unknown
- 2008-10-16 ES ES13154790.3T patent/ES2524910T3/es active Active
- 2008-10-16 SI SI200830579T patent/SI2215092T1/sl unknown
- 2008-10-16 PL PL08839793T patent/PL2215092T3/pl unknown
- 2008-10-16 CN CN201410312258.5A patent/CN104069112A/zh active Pending
- 2008-10-16 MY MYPI2010001693A patent/MY153979A/en unknown
- 2008-10-16 EP EP08839793A patent/EP2215092B1/fr active Active
- 2008-10-16 PT PT131547903T patent/PT2610258E/pt unknown
- 2008-10-16 CN CN200880112254.5A patent/CN101827852B/zh active Active
- 2008-10-16 EA EA201000609A patent/EA019480B1/ru not_active IP Right Cessation
- 2008-10-16 PT PT08839793T patent/PT2215092E/pt unknown
- 2008-10-16 CA CA2705414A patent/CA2705414C/fr active Active
- 2008-10-16 PL PL13154790T patent/PL2610258T3/pl unknown
- 2008-10-16 NZ NZ585346A patent/NZ585346A/en unknown
- 2008-10-17 PE PE2008001796A patent/PE20091386A1/es not_active Application Discontinuation
- 2008-10-17 TW TW097139983A patent/TWI421077B/zh active
- 2008-10-17 UY UY31405A patent/UY31405A1/es not_active Application Discontinuation
- 2008-10-17 CL CL2008003096A patent/CL2008003096A1/es unknown
- 2008-10-17 PE PE2013001391A patent/PE20131463A1/es not_active Application Discontinuation
- 2008-10-17 AR ARP080104560A patent/AR069075A1/es active IP Right Grant
-
2010
- 2010-03-09 ZA ZA201001683A patent/ZA201001683B/xx unknown
- 2010-04-16 TN TN2010000175A patent/TN2010000175A1/fr unknown
- 2010-05-05 EC EC2010010156A patent/ECSP10010156A/es unknown
- 2010-05-12 MA MA32832A patent/MA31845B1/fr unknown
-
2012
- 2012-04-23 CY CY20121100378T patent/CY1112703T1/el unknown
- 2012-12-03 JP JP2012264647A patent/JP5615889B2/ja active Active
-
2014
- 2014-11-26 CY CY20141100984T patent/CY1115858T1/el unknown
- 2014-11-26 HR HRP20141153AT patent/HRP20141153T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31845B1 (fr) | Pipéridino-dihydrothiénopyrimidines substituées | |
| NO20074615L (no) | Dihydrotienopyrimidiner for behandling av inflamatoriske sykdommer | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| EA200802051A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| TN2009000471A1 (fr) | Composes amino-heterocycliques | |
| ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
| MX2010003346A (es) | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| WO2007100366A3 (fr) | Modulateurs allostériques positifs du récepteur de la quinolone m1 | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA32798B1 (fr) | Acides naphtylacétiques | |
| NO20074617L (no) | Nye forbindelser for behandling av inflamotoriske sykdommer | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| ATE507226T1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung | |
| WO2009117283A3 (fr) | Modulateurs allostériques positifs du récepteur m1 de la quinolizidine | |
| WO2009134668A3 (fr) | Modulateurs allostériques positifs pour le récepteur m1 de 4-oxo-1,4-dihydroquinoléine | |
| UA97944C2 (ru) | Соединения для лечения воспалительных заболеваний | |
| DE602004014261D1 (de) | Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten |